IN THE CLAIMS

I. Substitution of Claims

Please substitute pending claims 101, 102 and 149, with the corresponding amended claims, as shown below:

101. (Amended) A method for improving the efficacy of a pharmaceutical useful for treating erectile dysfunction in a male subject, comprising:

percutaneously administering to an area of skin of the subject a pharmacologically effective amount of a composition consisting essentially of:

a) about 0.5 % to about 10 % testosterone;

b) about 30 % to about 98 % alcohol selected from the group consisting of ethanol, and isopropanol;

c) about 0.1 % to about 5 % isopropyl myristate;

d) about 1 % to about 5 % sodium hydroxide; and

e) about 0.1 % to about 5 % gelling agent;

wherein the percentages are weight to weight of the composition.

102. (Amended) A method for improving the efficacy of a pharmaceutical useful for treating erectile dysfunction in a male subject, comprising:

percutaneously administering to the subject a pharmacologically effective amount of a composition consisting essentially of:

a) about 0.5 % to about 10 % testosterone;

b) about 30 % to about 98 % alcohol selected from the group consisting of ethanol, and isopropanol;

c) about 0.1 % to about 5 % isopropyl myristate;

d) about 1 % to about 5 % sodium hydroxide; and

e) about 0.1 % to about 5 % gelling agent; and

administering the pharmaceutical to the subject;

wherein the amount of the composition administered to the subject is sufficient to achieve an erection for sexual intercourse in the subject; and the percentages are weight to weight of the composition.

149. (Amended) A method for improving the efficacy of a pharmaceutical useful for treating erectile dysfunction in a male subject, comprising:

percutaneously administering to the subject a pharmacologically effective amount of a composition consisting essentially of:

a) about 0.5 % to about 10 % testosterone;

b) about 30 % to about 98 % alcohol selected from the group consisting of ethanol, and isopropanol;

c) about 0.1 % to about 5 % isopropyl myristate;

d) about 1 % to about 5 % sodium hydroxide; and

e) about 0.1 % to about 5 % gelling agent; and

administering the pharmaceutical to the subject;

wherein the amount of the composition administered to the subject is sufficient to achieve hormonal steady state levels of testosterone in the subject; and the percentages are weight to weight of the composition.